CA
NZ
UK
AU
IND
US
Cadence Design Systems officer Paul Scannell filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 2,401 shares of Cadence common stock with an aggregate market value of $768,127.92.
Global Industrial Company officer Manoj Shetty filed a Form 144 notice of proposed sale of 2,000 shares of common stock, dated November 9, 2026, through Morgan Stanley Smith Barney LLC.
Namrata Saroj, Chief Business Officer of Ocular Therapeutix, Inc., filed a Form 4 on November 9, 2026, disclosing the sale of 35,370 shares of common stock on November 5, 2026, pursuant to a Rule 10b5-1 automatic sale instruction to cover tax withholding obligations tied …
Franklin Financial Services Corporation filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing third-quarter net income of $8,535 thousand and nine-month net income of $21,783 thousand.
Artiva Biotherapeutics, Inc. filed a Form 8-K/A amendment on November 9, 2026, providing cost estimates for its previously announced wind-down of AlloNK development and workforce reduction that were unavailable at the time of the original October 27, 2026 filing.
American Public Education, Inc. filed a Form 8-K with the SEC on November 9, 2026, reporting that it issued a press release covering financial results for the three and nine months ended September 30, 2026.
Inogen, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $16.2 million for the quarter and a $10.6 million impairment charge recorded in …
Werner Enterprises, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a return to profitability in the third quarter after a loss in the same period a year earlier.
Thryv Holdings, Inc. (NASDAQ:THRY) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a going-concern warning and ongoing strategic initiatives including a planned divestiture of its print business.
WhiteHawk Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting continued operating losses and balance sheet changes following a mid-year private placement.
Please wait processing your request...